Bristol-Myers Beats Estimates on Key Cancer Drugs Like Opdivo

  • 2016 EPS forecast range of $2.30 to $2.40 above predictions
  • Sales of Opdivo, Eliquis topped estimates last quarter

Bristol-Myers Squibb Co.reported fourth-quarter earnings that topped analysts’ estimated and gave a 2016 profit forecast that’s also above predictions, driven by sales key cancer drug Opdivo and blood thinner Eliquis.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.